Skip to main content

Table 2 Overall and Progression Free Survival (All patients)

From: Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma

Cohort A (No Metformin) Cohort B (Metformin)
Overall Survival
 • 67.7% patients alive at 1 year • 88.2% patients alive at 1 year
 • 62.0% patients alive at 2 years • 73.3% patients alive at 2 years
 • 20.7% patients alive at 3 years • 73.3% patients alive at 3 years
Progression Free Survival
 • 36.6% patients free from progression at 1 year • 56.1% patients free from progression at 1 year
 • 31.3% patients free from progression at 2 years • 49.1% patients free from progression at 2 years